Table of Content

"1    INTRODUCTION    29
1.1    OBJECTIVES OF THE STUDY    29
1.2    MARKET DEFINITION    29
1.2.1    INCLUSIONS & EXCLUSIONS    29
1.3    MARKET SCOPE    30
1.3.1    YEARS COVERED FOR THE STUDY    30
1.4    CURRENCY    31
1.5    LIMITATIONS    31
1.6    MARKET STAKEHOLDERS    31
1.7    SUMMARY OF CHANGES    32
2    RESEARCH METHODOLOGY    33
2.1    RESEARCH DATA    33
FIGURE 1    RESEARCH DESIGN    33
2.1.1    SECONDARY DATA    34
2.1.1.1    Secondary sources    35
2.1.2    PRIMARY DATA    35
FIGURE 2    PRIMARY SOURCES    35
2.1.2.1    Key data from primary sources    36
2.1.2.2    Key industry insights    37
2.1.2.3    Breakdown of primary interviews    37
FIGURE 3    BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS    37
FIGURE 4    BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,  
DESIGNATION, AND REGION    38
2.2    MARKET SIZE ESTIMATION    38
FIGURE 5    REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION    39
FIGURE 6    MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH    39
2.2.1    GROWTH FORECAST    40
FIGURE 7    CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS    41
FIGURE 8    TOP-DOWN APPROACH    41
2.3    MARKET BREAKDOWN AND DATA TRIANGULATION    42
FIGURE 9    DATA TRIANGULATION METHODOLOGY    42
2.4    MARKET SHARE ANALYSIS    43
2.5    ASSUMPTIONS FOR THE STUDY    43
2.6    INDICATORS AND ASSUMPTIONS AND  THEIR IMPACT ON THE STUDY    44
2.6.1    COVID-19-SPECIFIC ASSUMPTIONS    45
2.7    RISK ASSESSMENT    45
TABLE 1    RISK ASSESSMENT    45
3    EXECUTIVE SUMMARY    46
FIGURE 10    MICROTOMES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)    46
FIGURE 11    MICROTOMES MARKET, BY TECHNOLOGY,  2022 VS. 2027 (USD MILLION)    47
FIGURE 12    MICROTOMES MARKET, BY APPLICATION,  2022 VS. 2027 (USD MILLION)    47
FIGURE 13    MICROTOMES MARKET, BY END USER,  2022 VS. 2027 (USD MILLION)    48
FIGURE 14    GLOBAL MICROTOMES MARKET: GEOGRAPHIC SNAPSHOT    49
4    PREMIUM INSIGHTS    50
4.1    MICROTOMES MARKET OVERVIEW    50
FIGURE 15    RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH    50
4.2    MICROTOMES MARKET, BY PRODUCT    50
FIGURE 16    FULLY AUTOMATED MICROTOMES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD    50
4.3    ASIA PACIFIC: MICROTOMES MARKET,  BY PRODUCT AND COUNTRY    51
FIGURE 17    ROTARY MICROTOMES SEGMENT WILL DOMINATE APAC MARKET DURING FORECAST PERIOD    51
4.4    GEOGRAPHIC SNAPSHOT OF MICROTOMES MARKET    52
FIGURE 18    MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD    52
5    MARKET OVERVIEW    53
5.1    INTRODUCTION    53
5.2    MARKET DYNAMICS    53
FIGURE 19    MICROTOMES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES    53
5.2.1    DRIVERS    53
5.2.1.1    Rising prevalence of cancer    53
TABLE 2    INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION)    54
TABLE 3    PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS,  
2015 VS. 2018 VS. 2035    54
5.2.1.2    Growing demand for digital pathology    55
5.2.1.3    Recommendations for cancer screening    55
5.2.1.4    Availability of reimbursement    56
5.2.2    CHALLENGES    56
5.2.2.1    Lack of skilled professionals    56
TABLE 4    NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018    57
5.2.2.2    Availability of refurbished products    57
5.2.3    OPPORTUNITIES    57
5.2.3.1    Growing focus on personalized medicine    57
5.2.3.2    Emerging economies    58
5.3    IMPACT OF COVID-19 ON MICROTOMES MARKET    58
5.4    RANGES/SCENARIOS    60
5.4.1    MICROTOMES MARKET    60
FIGURE 20    PESSIMISTIC SCENARIO    60
FIGURE 21    OPTIMISTIC SCENARIO    60
FIGURE 22    REALISTIC SCENARIO    61
5.5    VALUE CHAIN ANALYSIS    61
FIGURE 23    VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASE    62
5.6    SUPPLY CHAIN ANALYSIS    62
FIGURE 24    DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES    63
5.7    TECHNOLOGY ANALYSIS    63
5.8    PORTER’S FIVE FORCES ANALYSIS    64
5.8.1    THREAT OF NEW ENTRANTS    64
5.8.2    INTENSITY OF COMPETITIVE RIVALRY    64
5.8.3    BARGAINING POWER OF BUYERS    64
5.8.4    BARGAINING POWER OF SUPPLIERS    65
5.8.5    THREAT OF SUBSTITUTES    65
5.9    KEY STAKEHOLDERS & BUYING CRITERIA    65
5.9.1    KEY STAKEHOLDERS IN BUYING PROCESS    65
FIGURE 25    INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS    65
TABLE 5    INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS    65
5.9.2    BUYING CRITERIA    66
FIGURE 26    KEY BUYING CRITERIA FOR TOP 2 END USERS    66
TABLE 6    KEY BUYING CRITERIA FOR TOP 2 END USERS    66
5.10    REGULATORY LANDSCAPE    67
TABLE 7    INDICATIVE LIST OF REGULATORY AUTHORITIES
GOVERNING MICROTOMES MARKET    67
5.11    PATENT ANALYSIS    68
5.12    KEY CONFERENCES & EVENTS IN 2022    69
TABLE 8    LIST OF CONFERENCES & EVENTS    69
5.13    PRICING ANALYSIS    69
TABLE 9    PRICE RANGE FOR MICROTOMES    69
5.14    TRADE ANALYSIS    70
TABLE 10    IMPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF  INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS,  
BY COUNTRY, 2016–2020 (USD MILLION)    70
TABLE 11    EXPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF  INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS,  
BY COUNTRY, 2016–2020 (USD MILLION)    71
5.15    ECOSYSTEM ANALYSIS    71
5.15.1    ROLE IN ECOSYSTEM    72
5.15.2    KEY PLAYERS OPERATING IN MICROTOMES MARKET    72
5.16    TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES    73

6    MICROTOMES MARKET, BY PRODUCT    74
6.1    INTRODUCTION    75
TABLE 12    MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    75
TABLE 13    MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    75
6.2    MICROTOME INSTRUMENTS    76
TABLE 14    MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION)    76
TABLE 15    MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION)    76
TABLE 16    MICROTOME INSTRUMENTS MARKET, BY REGION,
2017–2020 (USD MILLION)    76
TABLE 17    MICROTOME INSTRUMENTS MARKET, BY REGION,
2021–2027 (USD MILLION)    77
6.2.1    ROTARY MICROTOMES    77
6.2.1.1    Rotary microtomes are widely used in histology laboratories    77
TABLE 18    ROTARY MICROTOMES OFFERED BY MARKET PLAYERS    77
TABLE 19    ROTARY MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)    78
TABLE 20    ROTARY MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)    78
6.2.2    CRYOSTAT MICROTOMES    79
6.2.2.1    Cryostat microtomes provide immediate results by quickly, reliably, and safely cutting accurate frozen sections    79
TABLE 21    CRYOSTAT MICROTOMES OFFERED BY MARKET PLAYERS    79
TABLE 22    CRYOSTAT MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)    80
TABLE 23    CRYOSTAT MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)    80
6.2.3    VIBRATING MICROTOMES    80
6.2.3.1    Vibrating microtomes are designed to cut fresh tissue specimens    80
TABLE 24    VIBRATING MICROTOMES OFFERED BY MARKET PLAYERS    81
TABLE 25    VIBRATING MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)    81
TABLE 26    VIBRATING MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)    81
6.2.4    OTHER MICROTOMES    82
TABLE 27    OTHER MICROTOMES OFFERED BY MARKET PLAYERS    83
TABLE 28    OTHER MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)    83
TABLE 29    OTHER MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)    84
6.3    MICROTOME ACCESSORIES    84
TABLE 30    MICROTOME ACCESSORIES MARKET, BY TYPE, 2017–2020 (USD MILLION)    84
TABLE 31    MICROTOME ACCESSORIES MARKET, BY TYPE, 2021–2027 (USD MILLION)    84
6.3.1    MICROTOME BLADES    85
6.3.1.1    Adoption of disposable blades has increased among end users    85
TABLE 32    MICROTOME BLADES OFFERED BY MARKET PLAYERS    85
TABLE 33    MICROTOME BLADES MARKET, BY REGION, 2017–2020 (USD MILLION)    86
TABLE 34    MICROTOME BLADES MARKET, BY REGION, 2021–2027 (USD MILLION)    86
6.3.2    OTHER MICROTOME ACCESSORIES    86
TABLE 35    OTHER MICROTOME ACCESSORIES OFFERED BY MARKET PLAYERS    87
TABLE 36    OTHER MICROTOME ACCESSORIES MARKET, BY REGION,
2017–2020 (USD MILLION)    88
TABLE 37    OTHER MICROTOME ACCESSORIES MARKET, BY REGION,
2021–2027 (USD MILLION)    88
7    MICROTOMES MARKET, BY TECHNOLOGY    89
7.1    INTRODUCTION    90
TABLE 38    MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    90
TABLE 39    MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    90
7.2    MANUAL MICROTOMES    90
7.2.1    LOWER COST AND USER COMFORT ASSOCIATED WITH THESE MICROTOMES ARE DRIVING THEIR ADOPTION    90
TABLE 40    MANUAL MICROTOMES OFFERED BY MARKET PLAYERS    91
TABLE 41    MANUAL MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)    91
TABLE 42    MANUAL MICROTOMES MARKET, BY REGION, 2021–2027 USD MILLION)    91
7.3    SEMI-AUTOMATED MICROTOMES    92
7.3.1    SEMI-AUTOMATED MICROTOMES SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD    92
TABLE 43    SEMI-AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS    92
TABLE 44    SEMI-AUTOMATED MICROTOMES MARKET, BY REGION,
2017–2020 (USD MILLION)    92
TABLE 45    SEMI-AUTOMATED MICROTOMES MARKET, BY REGION,
2021–2027 (USD MILLION)    93
7.4    FULLY AUTOMATED MICROTOMES    93
7.4.1    LACK OF CLINICAL LABORATORY TECHNICIANS AND HIGH PREVALENCE OF CANCER HAVE DRIVEN SEGMENT GROWTH    93
TABLE 46    FULLY AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS    93
TABLE 47    FULLY AUTOMATED MICROTOMES MARKET, BY REGION,
2017–2020 (USD MILLION)    94
TABLE 48    FULLY AUTOMATED MICROTOMES MARKET, BY REGION,
2021–2027 (USD MILLION)    94
8    MICROTOMES MARKET, BY APPLICATION    95
8.1    INTRODUCTION    96
TABLE 49    MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    96
TABLE 50    MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    96
8.2    DISEASE DIAGNOSIS    96
8.2.1    EXPANDING POOL OF GERIATRIC PATIENTS AND INCREASING DIAGNOSIS OF CHRONIC DISEASES DRIVING SEGMENT GROWTH    96
TABLE 51    INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION)    97
TABLE 52    MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION,  
2017–2020 (USD MILLION)    97
TABLE 53    MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION,  
2021–2027 (USD MILLION)    97
8.3    MEDICAL RESEARCH    98
8.3.1    INCREASING RESEARCH ACTIVITIES TO DRIVE  ADOPTION OF MICROTOMES    98
TABLE 54    MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION,  
2017–2020 (USD MILLION)    98
TABLE 55    MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION,  
2021–2027 (USD MILLION)    98
9    MICROTOMES MARKET, BY END USER    99
9.1    INTRODUCTION    100
TABLE 56    MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    100
TABLE 57    MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    100
9.2    HOSPITAL LABORATORIES    100
9.2.1    HOSPITAL LABORATORIES ACCOUNTED FOR LARGEST
 MARKET SHARE IN 2021    100
TABLE 58    MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION,  
2017–2020 (USD MILLION)    101
TABLE 59    MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION,  
2021–2027 (USD MILLION)    101
9.3    CLINICAL LABORATORIES    102
9.3.1    PRESENCE OF ROBUST INFRASTRUCTURE TO PERFORM TESTS IN HIGH VOLUMES IS ESTIMATED TO DRIVE MARKET GROWTH    102
TABLE 60    MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION,  
2017–2020 (USD MILLION)    102
TABLE 61    MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION,  
2021–2027 (USD MILLION)    102
9.4    OTHER END USERS    103
TABLE 62    MICROTOMES MARKET FOR OTHER END USERS, BY REGION,
2017–2020 (USD MILLION)    103
TABLE 63    MICROTOMES MARKET FOR OTHER END USERS, BY REGION,
2021–2027 (USD MILLION)    103
10    MICROTOMES MARKET, BY REGION    104
10.1    INTRODUCTION    105
TABLE 64    MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)    105
TABLE 65    MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)    105
10.2    NORTH AMERICA    106
FIGURE 27    NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035    106
FIGURE 28    NORTH AMERICA: MICROTOMES MARKET SNAPSHOT    107
TABLE 66    NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,
2017–2020 (USD MILLION)    108
TABLE 67    NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,
2021–2027 (USD MILLION)    108
TABLE 68    NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION)    108
TABLE 69    NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION)    108
TABLE 70    NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE,  
2017–2020 (USD MILLION)    109
TABLE 71    NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE,  
2021–2027 (USD MILLION)    109
TABLE 72    NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    109
TABLE 73    NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    110
TABLE 74    NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    110
TABLE 75    NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    110
TABLE 76    NORTH AMERICA: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION)    110
TABLE 77    NORTH AMERICA: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION)    111
10.2.1    US    111
10.2.1.1    High burden of cancer and numerous conferences on anatomic pathology to drive market growth    111
TABLE 78    US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040    111
TABLE 79    US: KEY MACROINDICATORS    112
TABLE 80    US: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    112
TABLE 81    US: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    112
TABLE 82    US: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    113
TABLE 83    US: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    113
TABLE 84    US: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    113
TABLE 85    US: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    113
TABLE 86    US: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    114
TABLE 87    US: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    114
10.2.2    CANADA    114
10.2.2.1    Availability of research funding and rising incidence of cancer to drive market growth    114
TABLE 88    CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    115
TABLE 89    CANADA: KEY MACROINDICATORS    115
TABLE 90    CANADA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    115
TABLE 91    CANADA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    116
TABLE 92    CANADA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    116
TABLE 93    CANADA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    116
TABLE 94    CANADA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    116
TABLE 95    CANADA: MICROTOMES MARKET, BY TECHNOLOGY,
 2021–2027 (USD MILLION)    117
TABLE 96    CANADA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    117
TABLE 97    CANADA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    117
10.3    EUROPE    117
FIGURE 29    EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035    118
TABLE 98    EUROPE: MICROTOMES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)    118
TABLE 99    EUROPE: MICROTOMES MARKET, BY COUNTRY, 2021–2027 (USD MILLION)    118
TABLE 100    EUROPE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    119
TABLE 101    EUROPE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    119
TABLE 102    EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION)    119
TABLE 103    EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION)    119
TABLE 104    EUROPE: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    120
TABLE 105    EUROPE: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    120
TABLE 106    EUROPE: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    120
TABLE 107    EUROPE: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    120
TABLE 108    EUROPE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    121
TABLE 109    EUROPE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    121
10.3.1    GERMANY    121
10.3.1.1    Increasing prevalence of chronic diseases to drive market growth    121
TABLE 110    GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    122
TABLE 111    GERMANY: MICROTOMES MARKET, BY PRODUCT,
 2017–2020 (USD MILLION)    122
TABLE 112    GERMANY: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION)    122
TABLE 113    GERMANY: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    123
TABLE 114    GERMANY: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    123
TABLE 115    GERMANY: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    123
TABLE 116    GERMANY: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    123
TABLE 117    GERMANY: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION)    124
TABLE 118    GERMANY: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION)    124
10.3.2    FRANCE    124
10.3.2.1    High prevalence of cancer to support market growth in France    124
TABLE 119    FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    125
TABLE 120    FRANCE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    125
TABLE 121    FRANCE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    125
TABLE 122    FRANCE: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    125
TABLE 123    FRANCE: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    126
TABLE 124    FRANCE: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    126
TABLE 125    FRANCE: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    126
TABLE 126    FRANCE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    126
TABLE 127    FRANCE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    127
10.3.3    UK    127
10.3.3.1    Favorable government initiatives to drive market growth    127
TABLE 128    UK: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    127
TABLE 129    UK: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    128
TABLE 130    UK: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    128
TABLE 131    UK: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    128
TABLE 132    UK: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    128
TABLE 133    UK: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    129
TABLE 134    UK: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    129
TABLE 135    UK: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    129
10.3.4    ITALY    129
10.3.4.1    High prevalence of cancer and increasing per capita healthcare spending to support market growth in Italy    129
TABLE 136    ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    130
TABLE 137    ITALY: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    130
TABLE 138    ITALY: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    131
TABLE 139    ITALY: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    131
TABLE 140    ITALY: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    131
TABLE 141    ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    131
TABLE 142    ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    132
TABLE 143    ITALY: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    132
TABLE 144    ITALY: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    132
10.3.5    SPAIN    132
10.3.5.1    High incidence of chronic diseases to drive market growth  in Spain    132
TABLE 145    SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    133
TABLE 146    SPAIN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    133
TABLE 147    SPAIN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    133
TABLE 148    SPAIN: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    134
TABLE 149    SPAIN: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    134
TABLE 150    SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,
 2017–2020 (USD MILLION)    134
TABLE 151    SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    134
TABLE 152    SPAIN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    135
TABLE 153    SPAIN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    135
10.3.6    REST OF EUROPE    135
TABLE 154    LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040    136
TABLE 155    LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040    136
TABLE 156    ROE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    137
TABLE 157    ROE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    137
TABLE 158    ROE: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    137
TABLE 159    ROE: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    137
TABLE 160    ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    138
TABLE 161    ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    138
TABLE 162    ROE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    138
TABLE 163    ROE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    138
10.4    ASIA PACIFIC    139
FIGURE 30    ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035    139
FIGURE 31    ASIA PACIFIC: MICROTOMES MARKET SNAPSHOT    140
TABLE 164    ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,
 2017–2020 (USD MILLION)    140
TABLE 165    ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,
2021–2027 (USD MILLION)    141
TABLE 166    ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,
 2017–2020 (USD MILLION)    141
TABLE 167    ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION)    141
TABLE 168    ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,
 2017–2020 (USD MILLION)    141
TABLE 169    ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION)    142
TABLE 170    ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    142
TABLE 171    ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    142
TABLE 172    ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,
 2017–2020 (USD MILLION)    142
TABLE 173    ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    143
TABLE 174    ASIA PACIFIC: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION)    143
TABLE 175    ASIA PACIFIC: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION)    143
10.4.1    JAPAN    143
10.4.1.1    Presence of well-developed healthcare system to support market growth in Japan    143
TABLE 176    JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040    144
TABLE 177    JAPAN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    144
TABLE 178    JAPAN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    145
TABLE 179    JAPAN: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    145
TABLE 180    JAPAN: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    145
TABLE 181    JAPAN: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    145
TABLE 182    JAPAN: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    146
TABLE 183    JAPAN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    146
TABLE 184    JAPAN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    146
10.4.2    CHINA    146
10.4.2.1    Rising healthcare expenditure to drive market growth in China    146
TABLE 185    CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    147
TABLE 186    CHINA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    147
TABLE 187    CHINA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    147
TABLE 188    CHINA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    148
TABLE 189    CHINA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    148
TABLE 190    CHINA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    148
TABLE 191    CHINA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    148
TABLE 192    CHINA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    149
TABLE 193    CHINA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    149
10.4.3    INDIA    149
10.4.3.1    Growing healthcare sector to drive market growth in India    149
TABLE 194    INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    149
TABLE 195    INDIA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    150
TABLE 196    INDIA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    150
TABLE 197    INDIA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    150
TABLE 198    INDIA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    151
TABLE 199    INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    151
TABLE 200    INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    151
TABLE 201    INDIA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    151
TABLE 202    INDIA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    152
10.4.4    REST OF ASIA PACIFIC    152
TABLE 203    ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040    153
TABLE 204    ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    153
TABLE 205    ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    153
TABLE 206    ROAPAC: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION)    153
TABLE 207    ROAPAC: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION)    154
TABLE 208    ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION)    154
TABLE 209    ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION)    154
TABLE 210    ROAPAC: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    154
TABLE 211    ROAPAC: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    155
10.5    REST OF THE WORLD    155
TABLE 212    LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025    155
TABLE 213    LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
 2018 VS. 2025    155
TABLE 214    BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025    156
TABLE 215    AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025    156
TABLE 216    ROW: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)    156
TABLE 217    ROW: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)    157
TABLE 218    ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION)    157
TABLE 219    ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION)    157
TABLE 220    ROW: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)    157
TABLE 221    ROW: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)    158
TABLE 222    ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)    158
TABLE 223    ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)    158
TABLE 224    ROW: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)    158
TABLE 225    ROW: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)    159
11    COMPETITIVE LANDSCAPE    160
11.1    OVERVIEW    160
11.2    KEY PLAYER STRATEGIES/RIGHT TO WIN    160
TABLE 226    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS    160
11.3    MARKET SHARE ANALYSIS    161
TABLE 227    MICROTOMES MARKET: DEGREE OF COMPETITION    161
11.4    COMPANY EVALUATION MATRIX    162
11.4.1    STARS    162
11.4.2    EMERGING LEADERS    163
11.4.3    PERVASIVE PLAYERS    163
11.4.4    PARTICIPANTS    163
FIGURE 32    COMPANY EVALUATION MATRIX: MICROTOMES MARKET    163
11.5    COMPANY EVALUATION MATRIX FOR SMES/START-UPS    164
11.5.1    PROGRESSIVE COMPANIES    164
11.5.2    STARTING BLOCKS    164
11.5.3    RESPONSIVE COMPANIES    164
11.5.4    DYNAMIC COMPANIES    164
FIGURE 33    COMPANY EVALUATION MATRIX FOR SMES/START-UPS:
MICROTOMES MARKET    165
11.6    COMPANY FOOTPRINT ANALYSIS    166
TABLE 228    OVERALL FOOTPRINT OF COMPANIES    166
TABLE 229    REGIONAL FOOTPRINT OF COMPANIES    167
TABLE 230    PRODUCT FOOTPRINT OF COMPANIES    168
11.7    COMPETITIVE BENCHMARKING    169
TABLE 231    MICROTOMES MARKET: DETAILED LIST OF KEY START-UPS/SMES    169
11.8    COMPETITIVE SCENARIO    170
11.8.1    PRODUCT LAUNCHES    170
TABLE 232    KEY PRODUCT LAUNCHES    170
11.8.2    DEALS    170
TABLE 233    KEY DEALS    170
11.8.3    OTHER DEVELOPMENTS    170
TABLE 234    OTHER KEY DEVELOPMENTS    170
12    COMPANY PROFILES    171
12.1    KEY PLAYERS    171
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1    DANAHER CORPORATION    171
TABLE 235    DANAHER CORPORATION: BUSINESS OVERVIEW    171
FIGURE 34    DANAHER CORPORATION: COMPANY SNAPSHOT (2021)    172
12.1.2    PHC HOLDINGS CORPORATION    175
TABLE 236    PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW    175
FIGURE 35    PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)    176
12.1.3    CARDINAL HEALTH    178
TABLE 237    CARDINAL HEALTH: BUSINESS OVERVIEW    178
FIGURE 36    CARDINAL HEALTH: COMPANY SNAPSHOT (2021)    179
12.1.4    BOECKELER INSTRUMENTS, INC.    181
TABLE 238    BOECKELER INSTRUMENTS, INC.: BUSINESS OVERVIEW    181
12.1.5    BRIGHT INSTRUMENTS LTD.    183
TABLE 239    BRIGHT INSTRUMENTS LTD.: BUSINESS OVERVIEW    183
12.1.6    ERMA INC.    184
TABLE 240    ERMA INC.: BUSINESS OVERVIEW    184
12.1.7    HISTO-LINE LABORATORIES    185
TABLE 241    HISTO-LINE LABORATORIES: BUSINESS OVERVIEW    185
12.1.8    JINHUA YIDI MEDICAL APPLIANCE CO., LTD.    187
TABLE 242    JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: BUSINESS OVERVIEW    187
12.1.9    MEDIMEAS    189
TABLE 243    MEDIMEAS: BUSINESS OVERVIEW    189
12.1.10    MEDITE MEDICAL GMBH    191
TABLE 244    MEDITE MEDICAL GMBH: BUSINESS OVERVIEW    191
12.1.11    MICROTEC LABORGERÄTE GMBH    192
TABLE 245    MICROTEC LABORGERÄTE GMBH: BUSINESS OVERVIEW    192
12.1.12    SAKURA FINETEK USA, INC.    194
TABLE 246    SAKURA FINETEK USA, INC.: BUSINESS OVERVIEW    194
12.1.13    SLEE MEDICAL GMBH    196
TABLE 247    SLEE MEDICAL GMBH: BUSINESS OVERVIEW    196
12.1.14    SM SCIENTIFIC INSTRUMENTS PVT. LTD.    198
TABLE 248    SM SCIENTIFIC INSTRUMENTS PVT. LTD.: BUSINESS OVERVIEW    198
12.1.15    TED PELLA, INC.    200
TABLE 249    TED PELLA, INC.: BUSINESS OVERVIEW    200
12.2    OTHER PLAYERS    202
12.2.1    AGD BIOMEDICALS PVT. LTD.    202
TABLE 250    AGD BIOMEDICALS PVT. LTD.: BUSINESS OVERVIEW    202
12.2.2    AMOS SCIENTIFIC PTY LTD.    203
TABLE 251    AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW    203
12.2.3    CAMPDEN INSTRUMENTS LTD.    204
TABLE 252    CAMPDEN INSTRUMENTS LTD.: BUSINESS OVERVIEW    204
12.2.4    DIAPATH S.P.A.    205
TABLE 253    DIAPATH S.P.A.: BUSINESS OVERVIEW    205
12.2.5    LABOID INTERNATIONAL    207
TABLE 254    LABOID INTERNATIONAL: BUSINESS OVERVIEW    207
12.2.6    LAFAYETTE INSTRUMENT COMPANY    208
TABLE 255    LAFAYETTE INSTRUMENT COMPANY: BUSINESS OVERVIEW    208
12.2.7    LUPETEC    209
TABLE 256    LUPETEC: BUSINESS OVERVIEW    209
12.2.8    MILESTONE MEDICAL    210
TABLE 257    MILESTONE MEDICAL: BUSINESS OVERVIEW    210
12.2.9    RWD LIFE SCIENCE CO., LTD.    211
TABLE 258    RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW    211
12.2.10    SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD.    212
TABLE 259    SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW    212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13    APPENDIX    213
13.1    DISCUSSION GUIDE    213
13.2    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    216
13.3    AVAILABLE CUSTOMIZATIONS    218
13.4    RELATED REPORTS    218
13.5    AUTHOR DETAILS    219"